AZN News and Press, AstraZeneca PLC From 03/19/24

2024-03-19 13:15:03 ET Summary AstraZeneca is acquiring Fusion Pharmaceuticals for up to $2.4 billion to expand its presence in the radiopharmaceuticals market. The acquisition includes Fusion's late-stage radiopharmaceutical candidate, FPI-2265, a potential treatment of metastati...

2024-03-19 12:31:34 ET More on Actinium Pharmaceuticals Actinium Pharmaceuticals: Closer To Realizing Its Potential (Rating Upgrade) Actinium shares surge on promising data for AML radiotherapy candidate Actinium, Fusion stocks rally on $4.1B RayzeBio takeover deal ...

2024-03-19 10:16:19 ET Summary Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows. Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations ...

Includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage ...

2024-03-19 05:43:23 ET More on related stocks: StoneCo Q4 Earnings: I Made A Mistake (Rating Downgrade) StoneCo Ltd. (STNE) Q4 2023 Earnings Call Transcript National CineMedia, Inc. (NCMI) Q4 2023 Earnings Call Transcript AstraZeneca will buy Fusion Pharmaceu...

2024-03-19 04:10:27 ET More on AstraZeneca & Fusion Pharmaceuticals 5 Reasons AstraZeneca Stock Can Rise In 2024 Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook AstraZeneca to cap costs of inhalers at $35 per month AstraZeneca to expand ...

2024-03-18 15:36:31 ET More on Puma Biotechnology Puma Biotechnology, Inc. 2023 Q4 - Results - Earnings Call Presentation Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Puma Biotechnology Historical ear...

2024-03-18 12:17:28 ET More on AstraZeneca 5 Reasons AstraZeneca Stock Can Rise In 2024 AstraZeneca PLC (AZN) Q4 2023 Earnings Call Transcript AstraZeneca FY23 Earnings Review: It's OK To Buy Dip On Q4 Bottom Line Miss AstraZeneca to expand rare disease pipel...

2024-03-18 10:00:07 ET Summary Novo Nordisk's Wegovy represents a significant advancement in obesity treatment, demonstrating a more profound weight-loss effect compared to its predecessor, Saxenda. Eli Lilly's entry with Zepbound, targeting both GLP-1 and GIP, signifies a competi...

2024-03-18 07:04:31 ET Summary Today, we look at Mineralys Therapeutics, a clinical-stage biotechnology company focused on developing treatments for diseases driven by elevated aldosterone levels. The company's sole asset, lorundrostat, is an aldosterone synthase inhibitor that ha...